The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001066370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
14/08/2026
Date registered
Help: Date registered
28/08/2026
Date last updated
Help: Date last updated
19/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
28/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Mapping Extracranial Doppler Flow Dynamics During Physiological Provocation in Healthy Volunteers
Scientific title
Vessel-specific and inter-vessel extracranial and orbital Doppler blood flow responses to standardised physiological provocation in healthy adults aged 18 to 45 years: a single-centre, single-group, non-randomised Phase 0 study
Additional trial identifiers [1] 318244 0
Nil known
Universal Trial Number (UTN)
Trial acronym
FLOW-MAP
Related trial records

Health condition
Health condition(s) studied:
Acute neurological deterioration in sedated or non-communicative intensive care patients 343236 0
Cerebral large-vessel occlusion (ischaemic stroke) 343237 0
Cerebral vasospasm 343238 0
Raised intracranial pressure (intracranial hypertension) 343239 0
Delayed Cerebral Ischaemia 343421 0
Subarachnoid haemorrhage 343422 0
Condition category
Condition code
Neurological 339342 339342 0 0
Studies of the normal brain and nervous system
Stroke 339343 339343 0 0
Ischaemic
Cardiovascular 339415 339415 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Single group. All participants receive the same sequence of standardised, non-invasive physiological provocations during one recording session, delivered by trained study staff at the study site. There is no control or comparator group and no randomisation.

Staged enrolment — run-in group and expansion group: enrolment proceeds in two stages within this single group. The first 5 participants enrolled form the run-in group. Enrolment then continues to a total of up to 20 participants, who form the expansion group. The run-in group is not a separate study arm and does not receive a different exposure: run-in participants undergo exactly the same provocations, in the same order, with the same monitoring, visit schedule and follow-up as expansion participants. The run-in group exists solely as a feasibility and signal-quality checkpoint, to confirm that the multichannel Doppler configuration can reliably acquire analysable signals from the target vessels under study conditions. Progression to the expansion group is governed by a go / no-go review conducted by the sponsor scientific lead and the principal investigator, convened within 5 business days of the fifth run-in participant completing the main recording visit and the 24 hour safety follow-up, and held before any expansion-group enrolment. A go decision requires both of the following. First, signal quality: a first baseline recording of acceptable signal-to-noise, defined as the successful generation of numeric Doppler outputs (resistance index, pulsatility index, peak systolic and end diastolic values) over at least 10 seconds for at least 4 of the 6 target vessel sites, in at least 4 of the 5 run-in participants. Second, safety: no safety concerns and no serious adverse events attributable to ultrasound device use or probe fixation. If either criterion is not met, the review committee documents how to proceed, which may include pausing, modifying the procedure with ethics approval where required, applying other mitigations, or stopping. The decision is by consensus and is documented and signed by both reviewers. Any procedure change decided at that review is classified by its effect on the comparability of run-in and expansion data, and that classification determines whether run-in data are pooled with expansion data in the primary analysis. Only expansion-group participants are eligible for the imaging sub-study.

Setting and monitoring: the participant is positioned at a head-of-bed angle of 30 degrees and remains at that angle for the whole recording session; the bed is not moved between provocations. Continuous multichannel Doppler ultrasound recordings are made from the superficial temporal arteries (bilateral), the ophthalmic artery terminal branches including the supratrochlear arteries (bilateral), and the cervical internal carotid arteries. Electrocardiography and pulse oximetry are monitored continuously throughout. Non-invasive blood pressure is measured at baseline, immediately before the first trial of each provocation, and additionally as clinically indicated.

Establishing the stable baseline: once the Doppler probes are placed and secured in the fixation frame and the physiological monitoring is running, the participant lies at rest at the head-of-bed angle of 30 degrees for 3 minutes. A continuous 60 second baseline recording is then acquired. The baseline is accepted as stable when the operator confirms, immediately before the first provocation, that the Doppler signal at each target vessel is continuously present and free of movement or fixation artefact, and that heart rate and oxygen saturation are steady. If those conditions are not met, probe placement or fixation is adjusted, the rest period is extended and a further 60 second baseline is recorded; the first provocation does not begin until an acceptable baseline is obtained. The heart rate recorded over this baseline is documented as the session baseline heart rate and is the reference against which the bradycardia stop criterion is judged for the remainder of the session. This session baseline is separate from the pre-trial baseline that opens each individual provocation trial, described below; a pre-trial baseline commences only after the preceding recovery period is complete.

Provocations are performed in the following fixed order, with three repetitions each before moving to the next test:

Superficial temporal artery compression, performed bilaterally. Gentle compression is applied distal to the Doppler probes for 10 seconds per trial, three trials on the left side followed by three trials on the right side, released immediately on any symptom. Each recording block is 60 seconds: 30 seconds baseline, of which the final 10 seconds is the count-in, 10 seconds of compression, and 20 seconds of recorded recovery. Trials are separated by 60 seconds. If any stop criterion occurs on either side, no further superficial temporal artery compression is performed on either side and the participant is clinically evaluated.
Breath-hold. The participant exhales fully and holds at end-expiration (empty-lung breath-hold). Each recording block is 60 seconds: 10 seconds baseline, a 10 second count-in, a 20 second hold, and 20 seconds of recorded recovery. Trials are separated by 60 seconds. The participant may release the hold at any time.
Valsalva manoeuvre. Each recording block is 60 seconds: 10 seconds baseline, a 10 second count-in, a 10 second strain held at 40 mmHg against a digital manometer, and 30 seconds of recorded recovery. Trials are separated by 60 seconds. Two practice strains are performed during familiarisation.
Hyperventilation. Each recording block is 180 seconds: a 10 second count-in, 120 seconds of paced hyperventilation to a metronome at 30 breaths per minute, and 50 seconds of recorded recovery. Trials are separated by 2 minutes to allow carbon dioxide to normalise.
Common or internal carotid artery compression. Performed by an experienced clinician using gentle but firm pressure at the level of the neck, for a maximum of 5 seconds per trial, with immediate release if any symptom occurs. Three trials per side, with at least 2 minutes rest between trials. Each recording block is 60 seconds: 30 seconds baseline, occlusion of 5 seconds or less, and 25 seconds of recorded recovery.

Pre-specified stop criteria apply to every provocation: presyncope, chest pain, new neurological symptoms, new arrhythmia, or investigator concern; or any of the following numeric limits: oxygen saturation below 92 per cent; heart rate above 160 beats per minute; systolic blood pressure above 160 mmHg; diastolic blood pressure below 50 mmHg; or bradycardia, defined as whichever occurs first of a fall in heart rate of 30 beats per minute or more below the session baseline, or an absolute heart rate below 40 beats per minute. Where a limit is breached the actual value is recorded, the trial is stopped, the participant is returned to a safe position, and the value is escalated to the attending clinician. If a trial is terminated early, no further repeats of that provocation are attempted unless the clinician judges it safe and the participant wishes to continue.

Duration and adherence: individual participation is approximately 2 to 4 hours during one main recording visit. Screening occurs at a preceding visit, either on the same day immediately prior or up to 14 days earlier, and includes carotid duplex ultrasound. A telephone safety follow-up is made at 24 hours. Adherence is monitored by direct observation of every provocation by study staff, and each trial is recorded on the case report form.

Imaging sub-study: a subset of up to five participants, drawn only from the expansion group, also undergoes a single non-contrast magnetic resonance angiogram of the head, expected to take 60 to 90 minutes, within 0 to 14 days of the main recording visit. This is performed at a third-party imaging service provider on the investigator's referral. Selection of these participants is by invitation on the basis of MRI eligibility and the practical feasibility of scheduling the scan within that window; it is not determined by order of enrolment or order of opt-in, and run-in group participants are not eligible. MRI safety screening is performed by trained imaging staff. Participation in the sub-study is optional, and declining it does not affect participation in any other part of the study. If an invited participant declines, withdraws or cannot complete the scan, a replacement is invited from the remaining expansion group participants, up to a maximum of five completed scans.

The Doppler ultrasound and monitoring systems used are commercially available, off-the-shelf devices, used without modification and within their approved intended purpose, as measurement tools only. No investigational medical device is under study, and the study does not evaluate the safety, effectiveness or performance of any device.
Intervention code [1] 335074 0
Diagnosis / Prognosis
Intervention code [2] 335075 0
Early detection / Screening
Description of the comparator or control
No control group and no comparator arm. This is a single-group study in which each participant serves as their own reference: the response to every provocation is expressed as the change from that participant's own immediately preceding baseline recording, defined as the final 60 seconds of the stable pre-provocation period. No placebo, sham, active comparator or historical control is used, and no participant receives an alternative or control procedure.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346550 0
Magnitude of the Doppler blood flow response to each provocation, assessed as the within-participant percentage change from baseline in mean Doppler signal, peak systolic Doppler signal, end-diastolic Doppler signal, and the pulsatility-type and resistance-type waveform indices, reported separately by vessel, side and provocation. This is a composite primary outcome. Doppler recordings are made using the study's multichannel continuous-wave and duplex ultrasound equipment.
Timepoint [1] 346550 0
Baseline (the final 60 seconds of the stable pre-provocation period), then continuously from the onset of each provocation to 120 seconds after provocation onset, or to the end of the recovery window if that is longer. Assessed at each of the three repetitions of each of the five provocations during the single recording visit (Visit 1).
Primary outcome [2] 346551 0
Pattern of blood flow redistribution between vessels during each provocation, assessed as pre-specified inter-vessel Doppler signal ratios (superficial temporal to ophthalmic terminal branch, cervical internal carotid to ophthalmic terminal branch, superficial temporal to cervical internal carotid) and as left-to-right asymmetry of the bilateral vessels, together with their change from baseline. This is a composite primary outcome.
Timepoint [2] 346551 0
Baseline (the final 60 seconds of the stable pre-provocation period), then continuously from the onset of each provocation to 120 seconds after provocation onset, or to the end of the recovery window if that is longer. Assessed at each of the three repetitions of each of the five provocations during the single recording visit (Visit 1).
Primary outcome [3] 346552 0
Temporal characteristics of the Doppler blood flow response to each provocation, assessed as onset latency, time to peak, recovery time, and the proportion of trials showing no detectable response, reported separately by vessel, side and provocation. This is a composite primary outcome.
Timepoint [3] 346552 0
Baseline (the final 60 seconds of the stable pre-provocation period), then continuously from the onset of each provocation to 120 seconds after provocation onset, or to the end of the recovery window if that is longer. Assessed at each of the three repetitions of each of the five provocations during the single recording visit (Visit 1).
Secondary outcome [1] 466345 0
Between-participant variability of the baseline Doppler measures for each vessel, summarised as the between-participant standard deviation and coefficient of variation. This will be assessed as a composite outcome. The baseline measures are: mean Doppler signal over the cardiac cycle; peak systolic Doppler signal; end-diastolic Doppler signal; a pulsatility-type waveform index; and a resistance-type waveform index. Each measure is summarised for each vessel bilaterally: superficial temporal artery, ophthalmic artery terminal branch including the supratrochlear artery, and cervical internal carotid artery.
Timepoint [1] 466345 0
Baseline periods during the single recording visit (Visit 1), including the pre-provocation baseline preceding each of the five provocations.
Secondary outcome [2] 466346 0
Within-participant consistency of the Doppler response across repeated trials of the same provocation, summarised as the within-participant standard deviation and coefficient of variation for response magnitude and onset latency. This is a single composite outcome; the same summary measures are reported for each of the five provocations (superficial temporal artery compression, breath-hold, Valsalva manoeuvre, hyperventilation, and common or internal carotid artery compression). Three trials are performed per provocation, and three per side for the two compressions performed bilaterally.
Timepoint [2] 466346 0
Across the three repetitions of each of the five provocations during the single recording visit (Visit 1).
Secondary outcome [3] 466783 0
Association between the provocation-induced change in Doppler measures and the concurrent change in systemic physiological variables, namely heart rate and systolic, diastolic and mean arterial blood pressure, summarised as correlation coefficients. This will be assessed as a composite outcome.
Timepoint [3] 466783 0
Baseline (the final 60 seconds of the stable pre-provocation period) and during each trial of each of the five provocations, during the single recording visit (Visit 1).
Secondary outcome [4] 466784 0
Exploratory multivariate descriptors summarising the spatial and temporal pattern of the multichannel Doppler response across vessels and provocations. This will be assessed as a composite outcome.
Timepoint [4] 466784 0
Derived from the recordings made during the single recording visit (Visit 1); no separate assessment visit.
Secondary outcome [5] 466785 0
Incidence and nature of adverse events and serious adverse events. This will be assessed as a composite outcome. Events of specific interest are skin or allergic reactions related to ultrasound gel or contact materials; pressure-related effects at probe fixation or compression sites; and neurological or visual symptoms, including symptoms consistent with transient ischaemic attack or stroke.
Timepoint [5] 466785 0
From consent to the final study contact: at screening (Visit 0), throughout the recording visit (Visit 1), at the imaging visit (Visit 2) for imaging sub-study participants, and at the telephone follow-up conducted within 24 hours of the participant’s final on-site study procedure. Unresolved events are followed until resolution or stabilisation.

Eligibility
Key inclusion criteria
Healthy adult volunteers aged 18 to 45 years who are able to give written informed consent; who report good general health with no known significant cardiovascular, cerebrovascular or respiratory disease; and who are willing and able to comply with study procedures, including the physiological provocations.

Participants invited to the optional imaging sub-study must additionally be eligible for magnetic resonance imaging on standard safety screening.
Minimum age
18 Years
Maximum age
45 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
History of cerebral injury, including stroke, concussion, transient ischaemic attack, intracranial haemorrhage, subarachnoid haemorrhage, or known intracranial aneurysm or arteriovenous malformation.

Known carotid artery stenosis or aneurysm, or prior carotid surgery or stenting.

Unexplained syncope, significant arrhythmia, structural heart disease, or uncontrolled hypertension (for example systolic blood pressure of 160 mmHg or above, or diastolic blood pressure of 100 mmHg or above).

Chronic lung disease causing resting hypoxia or limiting participation in breath-hold or hyperventilation testing.

Current use of systemic anticoagulants or high-dose antiplatelet therapy, or medications affecting cerebrovascular tone or blood pressure.

Ophthalmic contraindications, including glaucoma and retinal disease.

Diabetes mellitus.

Pregnancy, or the possibility of pregnancy, as established by asking the participant in private. A urine or serum pregnancy test is not performed: the study involves no ionising radiation, no investigational product and no procedure with a known teratogenic risk, so a laboratory test is not proportionate to that risk. A response of possibly pregnant excludes the participant. Breastfeeding.

Implanted vagus nerve stimulator.

Any condition judged by the investigator to increase the risk of adverse events during the physiological provocations, for example severe migraine with aura or a seizure disorder.

For participants undergoing carotid compression: any abnormality on carotid duplex ultrasound deemed to increase risk, such as plaque, stenosis or aneurysm.

For participants invited to the optional imaging sub-study only: contraindications to magnetic resonance imaging, including implanted ferromagnetic devices, severe claustrophobia, or other standard magnetic resonance imaging safety exclusions.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety
Statistical methods / analysis
No formal power calculation has been performed. This is an exploratory, estimation-focused physiological study and it is not designed for confirmatory hypothesis testing, clinical efficacy assessment or diagnostic performance assessment, so a conventional power calculation would not be meaningful.

The target of up to 20 participants was set on feasibility grounds and to generate preliminary estimates to inform the design of future, larger studies. Recruitment proceeds in two stages: an initial run-in cohort of the first 5 participants, analysed descriptively for signal quality, procedural feasibility and safety; and, subject to pre-specified signal-quality progression criteria being met, expansion to a total of 20 participants. The progression criteria require successful generation of numeric Doppler outputs indicating at least 10 seconds of recording from at least four vessels in at least 4 of the 5 run-in participants, and no safety concerns attributable to the ultrasound equipment or probe fixation.

The sample of 20 is expected to provide preliminary estimates of between-participant and within-participant variability in the Doppler indices, to describe the range and typical magnitude of the dynamic response to each provocation, and to support exploratory multivariate analyses. An imaging sub-study subset of up to 5 participants is analysed descriptively only, with no formal statistical comparison against participants who do not undergo imaging.

Analyses are descriptive and estimation-based. No confirmatory alpha is allocated, no multiplicity adjustment is planned, and any p-values arising from supportive mixed-effects models are reported as nominal and exploratory only. The full analysis set comprises all participants with at least one usable baseline and at least one usable provocation recording.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment postcode(s) [1] 46943 0
3002 - East Melbourne

Funding & Sponsors
Funding source category [1] 322747 0
Commercial sector/Industry
Name [1] 322747 0
Wavewise Analytics Pty Ltd
Country [1] 322747 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Wavewise Analytics Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 325670 0
None
Name [1] 325670 0
Address [1] 325670 0
Country [1] 325670 0
Other collaborator category [1] 284058 0
University
Name [1] 284058 0
Australian Catholic University
Address [1] 284058 0
Country [1] 284058 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321188 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 321188 0
Ethics committee country [1] 321188 0
Australia
Date submitted for ethics approval [1] 321188 0
Approval date [1] 321188 0
15/05/2026
Ethics approval number [1] 321188 0
2026/PID01089 (SVHM local reference 088/26)

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152950 0
Prof Leonidas Karagounis
Address 152950 0
Australian Catholic University, Melbourne Campus (St Patrick's), The Mary Glowrey Building, 250 Victoria Parade, Fitzroy VIC 3065
Country 152950 0
Australia
Phone 152950 0
+61 497459279
Fax 152950 0
Email 152950 0
Contact person for public queries
Name 152951 0
Dr. Elliot Teo
Address 152951 0
Wavewise Analytics Pty Ltd. Level 2, 700 Swanston Street, Carlton 3053
Country 152951 0
Australia
Phone 152951 0
+61 477 575 785
Fax 152951 0
Email 152951 0
Contact person for scientific queries
Name 152952 0
Dr. Elliot Teo
Address 152952 0
Wavewise Analytics Pty Ltd. Level 2, 700 Swanston Street, Carlton 3053
Country 152952 0
Australia
Phone 152952 0
+61 477 575 785
Fax 152952 0
Email 152952 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• Published results
• Primary outcome(s)
• Safety data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
A finite period of: 15 years
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: email: [email protected] (Dr Elliot Teo, Sponsor Scientific Lead, Wavewise Analytics Pty Ltd)

• Postal address: Postal Address: Wavewise Analytics Pty Ltd, Level 2, 700 Swanston Street, Carlton VIC 3053, Australia

Are there extra considerations when requesting access to individual participant data?
Yes: Consent scope. Sharing of individual participant data is limited to participants who gave the separate optional consent for their de-identified individual data to be stored and shared for future research related to blood flow. Data from participants who declined that item will not be shared. Participants may withdraw that consent at any time, although data already shared may not be retrievable. Any restriction requested by a participant, or imposed by an ethics committee, remains attached to the data and must be honoured by any subsequent user.

Scope of the dataset. What is available is the de-identified participant-level dataset underlying the reported results: derived Doppler indices, response magnitudes, timing metrics and inter-vessel ratios, together with the associated demographic, safety and provocation-level variables and a data dictionary. Raw multichannel Doppler waveform recordings and the sponsor's signal-processing, feature-extraction and analysis methods are not part of this dataset. They are commercially sensitive and are the subject of intellectual property protection, and they are not required to verify the published analyses.

Imaging sub-study. De-identified magnetic resonance angiography data from the imaging sub-study are held in the DaRIS imaging management system operated by the University of Melbourne and are governed separately. Requests for that imaging are directed to the sponsor in the first instance and are subject to the same conditions, plus the requirements of the holding institution. Imaging carries a residual re-identification risk that requesters must address in their proposal.

Process and cost. Requests are considered on a case-by-case basis and there is no automatic right of access. A requester must provide a scientifically sound proposal, hold approval from a human research ethics committee or an equivalent lawful basis, and execute a data sharing or transfer agreement with the sponsor covering permitted use, security standards, publication controls, retention and secure disposal. The sponsor does not permit onward transfer of the data to third parties, or use of the data to develop commercial products or algorithms, except under separately negotiated terms. A cost-recovery fee may apply for data preparation. Requests are ordinarily acknowledged within 30 days.

Timing. Requests are accepted after publication of the main results. This is to protect the priority of pending intellectual property filings and to ensure the dataset is interpreted alongside the published methods. The sharing window aligns with the study's 15-year record retention period.




What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.